Gaelle Bego-Le-Bagousse
Overview
Explore the profile of Gaelle Bego-Le-Bagousse including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
75
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Hartford C, Alexis A, Wang Z, Levit N, Banderas B, Yaworsky A, et al.
Br J Dermatol
. 2025 Jan;
PMID: 39792566
Background: The prevalence and burden of atopic dermatitis (AD) are disproportionately high in individuals with skin of colour (SOC). Previous research shows that risk for xerosis and/or dyspigmentation is heightened...
2.
Kimball A, Delevry D, Yang M, Chuang C, Wang Z, Bego-Le-Bagousse G, et al.
Dermatol Ther (Heidelb)
. 2023 Aug;
13(9):2107-2120.
PMID: 37552431
Introduction: Atopic dermatitis (AD) can require long-term therapy. Few real-world studies have evaluated long-term effectiveness from the patients' perspective. The aim of this study was to evaluate patient-reported outcomes (PROs)...
3.
Silverberg J, Lynde C, Abuabara K, Patruno C, Benedetto A, Zhang H, et al.
Am J Clin Dermatol
. 2023 May;
24(4):673.
PMID: 37193879
No abstract available.
4.
Saeki H, Ohya Y, Nawata H, Arima K, Inukai M, Rossi A, et al.
J Clin Med
. 2023 Apr;
12(8).
PMID: 37109324
Pediatric atopic dermatitis (AD) can negatively impact the family quality of life (QoL). We report data from the real-world Epidemiology of Children with Atopic Dermatitis Reporting on their Experience (EPI-CARE)...
5.
Silverberg J, Lynde C, Abuabara K, Patruno C, Benedetto A, Zhang H, et al.
Am J Clin Dermatol
. 2023 Feb;
24(3):469-483.
PMID: 36808602
Background: Adults aged ≥ 60 years are often underrepresented in atopic dermatitis (AD) clinical trials; age-related comorbidities may impact treatment efficacy and safety. Objective: The aim was to report dupilumab...
6.
Silverberg J, Simpson E, Boguniewicz M, de Bruin-Weller M, Foley P, Kataoka Y, et al.
Acta Derm Venereol
. 2021 Oct;
101(11):adv00585.
PMID: 34618162
Optimal management of atopic dermatitis requires a comprehensive assessment of response to treatment in order to inform therapeutic decisions. In a real-world setting, successful response to atopic dermatitis treatment is...
7.
Deleuran M, Marcoux D, Bruin-Weller M, Irvine A, Baselga E, Ahn K, et al.
Acta Derm Venereol
. 2021 May;
101(7):adv00504.
PMID: 34043020
No abstract available.
8.
Drucker A, Qureshi A, Amand C, Villeneuve S, Gadkari A, Chao J, et al.
J Allergy Clin Immunol Pract
. 2017 Nov;
6(4):1342-1348.
PMID: 29174063
Background: Data on health care resource utilization (HCRU) and costs for patients with atopic dermatitis (AD) are lacking. Objective: The objective of this study was to determine HCRU and costs...
9.
Economic Evaluation of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis in Adults
Kuznik A, Bego-Le-Bagousse G, Eckert L, Gadkari A, Simpson E, Graham C, et al.
Dermatol Ther (Heidelb)
. 2017 Sep;
7(4):493-505.
PMID: 28933010
Introduction: Dupilumab significantly improves signs and symptoms of atopic dermatitis (AD), including pruritus, symptoms of anxiety and depression, and health-related quality of life versus placebo in adults with moderate-to-severe AD....
10.
OConnor P, Lublin F, Wolinsky J, Confavreux C, Comi G, Freedman M, et al.
J Neurol
. 2013 Jul;
260(10):2472-80.
PMID: 23852658
Multiple sclerosis (MS) relapses impose a substantial clinical and economic burden. Teriflunomide is a new oral disease-modifying therapy approved for the treatment of relapsing MS. We evaluated the effects of...